Answers are grounded in this paper and cite their sources.
MOTIVATION: Developing state-of-the-art RNA- and DNA-based therapeutics requires advanced computational frameworks that support the entire workflow - from biological rationale to the final drug construct - enabling tissue- and cell-specific targeting with high precision. Existing bioinformatics tools provide only partial solutions and rarely generate designs directly suitable for synthesis or preclinical evaluation. To address these limitations, we present BIOREDIS, a web-based platform for comprehensive nucleic acid therapeutic design. RESULTS: BIOREDIS integrates curated data from nine major biological resources and incorporates modules for coding sequence optimization, RNA interference (shRNA/siRNA) design, promoter/UTR selection, and automated construction of viral (AAV, lentiviral), non-viral, and mRNA vaccine vectors. The platform supports designs for human, mouse, and rat, with tissue-specific promoter recommendations available for human and mouse, and advanced cell-expression profiling natively restricted to human. BIOREDIS demonstrates competitive performance in coding sequence optimization and RNAi prediction, while uniquely providing an end-to-end workflow from target selection to fully specified next-generation DNA or RNA therapeutic constructs ready for synthesis and experimental validation. AVAILABILITY: BIOREDIS is freely available at https://rnadrug.ichb.pl/bioredis, with a mirror site at https://bioredis.cs.put.poznan.pl. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
No takes yet. Share an insight, caveat, or question.
Kubiś et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: